[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurogenic-bladder-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurogenic-bladder-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100640507","essential-oils-for-urinary-symptoms-in-multiple-sclerosis-patients-100640507",false,"NCT07599189","Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients","Efficacy and Safety of Essential Oil Aromatherapy on Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis: A Randomized Single-Blind Placebo-Controlled Clinical Trial.","AROMA-MS","Inclusion Criteria:\n\n* Confirmed diagnosis of Multiple Sclerosis (any form)\n* Documented lower urinary tract symptoms defined by an Overactive Bladder Symptom Score (OABSS) ≥ 3 at screening\n* Age between 18 and 65 years\n* Willing and able to provide written informed consent\n* Capable of performing daily topical self-application of the study oil, or having a caregiver available to assist throughout the study period\n\nExclusion Criteria:\n\n* Active urinary tract infection confirmed by urine culture at screening\n* Pre-existing urological condition unrelated to Multiple Sclerosis (e.g., bladder cancer, benign prostatic hyperplasia, or interstitial cystitis)\n* Known allergy or hypersensitivity to essential oils, apricot kernel oil, lavender, or rosemary\n* Active skin lesions, wounds, or dermatological conditions on the lower abdomen at the intended site of application\n* Pregnancy, breastfeeding, or planning to become pregnant during the study period\n* Significant cognitive impairment preventing understanding of study procedures or completion of questionnaires\n* Current use of an indwelling urinary catheter or practice of intermittent self-catheterization","ALL",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if essential oil aromatherapy works to improve urinary symptoms in adults with multiple sclerosis. It will also learn about the safety of essential oil use in this population.\n\nThe main questions it aims to answer are:\n\n* Does essential oil aromatherapy reduce urinary urgency, frequency, and incontinence episodes in participants with multiple sclerosis?\n* What medical problems do participants have when using essential oil aromatherapy?\n\nResearchers will compare essential oil aromatherapy to a placebo (a look-alike neutral oil with no therapeutic properties) to see if essential oil aromatherapy works to improve urinary symptoms in multiple sclerosis patients.\n\nParticipants will:\n\n* Use essential oil aromatherapy or a placebo oil every day for 6 weeks\n* Complete a urinary symptom scales to record the frequency, urgency, and any leakage episodes each day\n* Fill out quality of life questionnaires at the beginning and end of the study",[26,27,28,29,30],"Multiple Sclerosis (MS)","Neurogenic Bladder Disorder","Urinary Incontinence (UI)","Urinary Urgency","Lower Urinary Tract Symptoms (LUTS)","NOT_YET_RECRUITING","2026-05-16",{"date":34,"type":35},"2026-05-20","ACTUAL",{"date":37,"type":20},"2026-09",{"date":39,"type":20},"2027-03",{"name":41,"class":42},"University of Oran 1","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100631949","turkish-version-of-the-neurogenic-bladder-symptom-score-short-form-100631949","NCT07507331","Turkish Version of the Neurogenic Bladder Symptom Score Short Form","Turkish Version of the Neurogenic Bladder Symptom Score Short Form: Cross-Cultural Adaptation and Validation-Reliability Study","Inclusion Criteria:\n\n* Being ≥18 years old\n\n  * Having a diagnosis of Spinal Cord Injury (SCI) or Multiple Sclerosis (MS) and neurogenic lower urinary tract dysfunction\n  * Being able to read and understand Turkish and have the cognitive ability to independently complete questionnaires\n  * Can be included with any bladder management method (spontaneous voiding, CIC, permanent catheter, condom catheter, reconstruction\u002Fdiversion etc.)\n  * Volunteering and signing informed consent\n\nExclusion Criteria:\n\n* Having an active urinary tract infection (UTI)\n* Having undergone urological surgery in the last month\n* Reporting changes in bladder\u002Furinary function between the first and second applications (surgery, UTI, change in bladder medication)\n* Having a significant recent change in general health status\n* Having a spinal cord injury (SCI) in the spinal shock phase\n* Having experienced a relapse of Multiple Sclerosis (MS) within the last 3 months.","18 Years",{"count":53,"type":20},120,"OBSERVATIONAL","This observational study aims to evaluate the cross-cultural adaptation and psychometric properties of the Turkish version of the Neurogenic Bladder Symptom Score Short Form (NBSS-SF) in adults with spinal cord injury or multiple sclerosis who have neurogenic lower urinary tract dysfunction. Neurogenic bladder symptoms, such as urinary incontinence, urgency, and difficulties with urine storage or emptying, may negatively affect daily functioning and quality of life. In this study, the validity and reliability of the Turkish NBSS-SF will be examined, and convergent validity will be assessed through its relationship with the King's Health Questionnaire (KHQ) and the Short Form-12 (SF-12). In eligible participants, the scale will be administered again after 7 to 14 days. The aim of the study is to provide a valid and reliable Turkish patient-reported outcome measure for use in clinical practice and research.",[27,57,58,59],"Spinal Cord Injury","Multiple Sclerosis","Lower Urinary Track Symptoms",[61,62,57,58],"Neurogenic Bladder","Neurogenic Bladder Symptom Score- Short Form Validation","2026-04-07",{"date":65,"type":35},"2026-04-13",{"date":67,"type":20},"2026-03-27",{"date":69,"type":20},"2026-05",{"name":71,"class":42},"Gaziantep Islam Science and Technology University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100620298","define-final-selection-choice-criteria-for-a-coloplast-catheter-ensuring-highest-patient-satisfaction-via-surveys-eva-100620298","NCT07355803","Define Final Selection Choice Criteria for a Coloplast Catheter Ensuring Highest Patient Satisfaction Via Surveys (EVA).","EVA-study on Catheter Selection Criteria at Start of Self-catheterization","EVA","Inclusion Criteria:\n\n* Female or male aged eighteen years or older;\n* Written informed consent;\n* Subject affiliated with a social security scheme or beneficiary;\n* Subject with neurogenic or non-neurogenic bladder issues, justifying the implementation of intermittent self-catheterisation (ISC) to clean out the bladder;\n* Subject who received his\u002Fher initial ISC training at the time of inclusion;\n* Subject for whom the expected ISC duration is at least six months;\n* Subject for whom at least two types of Coloplast catheters have been introduced and who has chosen to use Coloplast catheters as the first catheter for self-catheterisation;\n* Subject able to independently conduct ISC;\n* Subject for whom the healthcare professional has recommended to conduct ISC at least four times per day.\n\nExclusion Criteria:\n\n* Vulnerable subject with regard to the current regulation:\n\n  * Pregnant, parturient or breast-feeding woman;\n  * Subject deprived of freedom by judicial, medical or administrative decision;\n  * Underage subject;\n  * Subject is legally protected or unable to express his\u002Fher consent;\n  * Subject not affiliated with or not a beneficiary of a social security scheme;\n  * Subject falling into several categories above;\n* Subject who refused to participate in the study;\n* Subject participating in an interventional clinical study;\n* Subject who, according to the investigator, has cognitive problems that prevent him\u002Fher from completing a questionnaire or for whom the assessment may be a problem.",{"count":81,"type":20},107,[23],"Understanding the Coloplast Intermittent Catheter Selection Study:\n\nThis study aims to understand how adults who need to use catheters to empty their bladder by themselves decide which Coloplast catheter works best for them. The two types of catheters studied are called SpeediCath and Luja.\n\nWhy is this study being done? The study wants to find out which catheter type helps people feel most satisfied when they start to use it on their own. It also looks at why people choose their catheter at the beginning, how happy they are with it over the first six months, and what problems they might face using it.\n\nWho can join the study?\n\n* Adults aged 18 or older who have bladder problems and need to empty their bladder using a catheter.\n* People who have been trained on how to use a catheter.\n* People who have chosen to use either SpeediCath or Luja catheters from Coloplast.\n* People who can perform the catheterization themselves at least two times per day.\n\nCertain people cannot join, such as pregnant women, anyone who cannot give consent, or those who have trouble filling out questionnaires.\n\nWhat will happen in the study?\n\nParticipants will visit the study center three times:\n\n* At the start (to select their catheter and answer questions about the reasons for the specific catheter selection)\n* After 3 to 12 weeks (to share their perception on the impact of the used catheter)\n* After 6 months (to measure final satisfaction and any difficulties)\n\nIf a participant changes to a different catheter type or catheter brand during the study, this will be recorded, and they will continue in the study.\n\nHow will this study help? The information gathered will help healthcare providers understand what matters most to people when selecting a catheter. This can improve how catheters are recommended and support patients better during self-catheterization and improve treatment adherence and compliance.",[27,85,86,87],"Non-Neurogenic Bladder","Bladder Dysfunction","Urinary Retention","RECRUITING","2026-01-13",{"date":91,"type":35},"2026-01-21",{"date":93,"type":35},"2025-10-21",{"date":95,"type":20},"2026-10-28",{"name":97,"class":98},"Coloplast NV\u002FSA","INDUSTRY",1]